MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ijrobp.2007.09.048

Медицинская библиотека · International journal of radiation oncology, biology, physics · 2007

HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.

De Ruysscher Dirk, Wanders Rinus, van Haren Erik, Hochstenbag Monique, Geraedts Wiel, Pitz Cordula, Simons Jean, Boersma Liesbeth, Verschueren Tom, Minken Andre, Bentzen Søren M, Lambin Philippe

Клиническое исследование I фазыКлиническое исследование II фазыСтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: To determine the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer (NSCLC).

PATIENTS AND

METHODS

In a prospective, Phase I/II study, according to the risk for radiation pneumonitis, three risk groups were defined: V(20) <25%, V(20) 25-37%, and V(20) >37%. The dose was administered in three steps from 61.2 Gy/34 fractions/23 days to 64.8 Gy/36 fractions/24 days to 68.40 Gy/38 fractions/25 days (1.8 Gy b.i.d. with 8-h interval), using a three-dimensional conformal technique. Only the mediastinal lymph node areas that were positive on the pretreatment (18)F-deoxy-D-glucose positron emission tomography scan were included in the target volume. The primary endpoint was toxicity.

RESULTS

A total of 48 Stage I-IIIB patients were included. In all risk groups, 68.40 Gy/38 fractions/25 days could be administered. Maximal toxicity according to the risk groups was as follows: V(20) <25% (n = 35): 1 Grade 4 (G4) lung and 1 G3 reversible esophageal toxicity; V(20) 35-37% (n = 12): 1 G5 lung and 1 G3 reversible esophageal toxicity. For the whole group, local tumor recurrence occurred in 25% (95% confidence interval 14%-40%) of the patients, with 1 of 48 (2.1%; upper one-sided 95% confidence limit 9.5%) having an isolated nodal recurrence. The median actuarial overall survival was 20 months, with a 2-year survival rate of 36%.

CONCLUSIONS

High-dose continuous hyperfractionated accelerated radiotherapy up to a dose of 68.40 Gy/38 fractions/25 days (a biologic equivalent of approximately 80 Gy when delivered in conventional fractionation) in patients with inoperable NSCLC and a V(20) up to 37% is feasible.

Для цитирования: De Ruysscher Dirk, Wanders Rinus, van Haren Erik, Hochstenbag Monique, Geraedts Wiel, Pitz Cordula, Simons Jean, Boersma Liesbeth, Verschueren Tom, Minken Andre, Bentzen Søren M, Lambin Philippe. HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer.. International journal of radiation oncology, biology, physics. 2007. DOI: 10.1016/j.ijrobp.2007.09.048.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.